917894-05-4

Upstream product

• 917894-09-8 N-(2-chloro-5-mercaptophenyl)-N'-(3-methylthiophenyl)-N'-methyl-guanidine hydrochloride 
• 373-52-4 bromofluoromethane 
• 917894-23-6 N-(2-chloro-5-mercaptophenyl)-N'-methyl-N'-(3-thiomethylphenyl)guanidine 
• 593-70-4 R₃₂ 
• 458567-42-5 N-(3-(methylthio)phenyl)cyanamide 
• 222734-73-8 N-methyl-N-(3-(methylthio)phenyl)cyanamide 
• 70502-87-3 3-amino-4-chlorobenzenethiol 
• 1783-81-9 3-methylmercaptoaniline 
• 97-08-5 3-nitro-4-chlorosulfonyl chloride 
• 917894-08-7 N-(5-benzylthio-2-chlorophenyl)-N'-(3-methylthiophenyl)-N'-methyl-guanidine hydrochloride 
• 917894-07-6 2-chloro-5-S-benzyl-thioaniline hydrochloride 
• 917894-06-5 2-chloro-5-S-benzyl-thioaniline 

Relevant academic research and scientific papers

Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: Novel high-affinity NMDA receptor antagonists for imaging with PET

Two S-[18F]fluoroalkylated diarylguanidines were synthesized and evaluated in vitro as potential tracers for imaging of N-methyl-d-aspartate receptors (NMDARs) with positron emission tomography (PET). [18F]1 and [18F]10 we

IMAGING 18F OR 11C-LABELLED ALKYLTHIOPHENYL GUANIDINES

The invention provides a compound of formula (I); or a salt or solvate thereof, wherein: R1 is hydrogen or C1-4alkyl; R2 and R4 are each independently selected from C1-4 alkyl, [11C] C1 4alkyl, and [18F]-C1-4 fluoroalkyl provided that at least one of R2 and R4 is [11C] C1 4alkyl or [18F]-C1-4 fluoroalkyl; and R3 is halo. Such compounds having use for imaging central nervous system receptors.